Updates
Stay informed on recent developments in the world of biomarkers for bladder cancer surveillance
Why urinary biomarkers should be used for the surveillance of non-muscle-invasive bladder cancer
Clinical case presentation by Dr. Ekaterina Laukhtina (Moscow, Russia) Editorial comment by Morgan Rouprêt The implementation and advantages of urinary biomarkers for non-muscle-invasive-bladder (NMIBC) were discussed by an international expert panel at the 19th...
Compare your opinion with peers and Prof. Dr. Paolo Gontero
Jimmy is a 68-year-old retired kindergarten teacher. Whenever he can, he volunteers to read to children during story time at the local library. He was first diagnosed with low-grade non-muscle-invasive bladder cancer (NMIBC) 12 years ago. Since then, he has had two...
The role of biomarkers in the diagnostic process of bladder carcinoma
Watch the presentation of Dr. Félix Guerrero Ramos (Madrid, Spain) The virtual 1st International Workshop in Urothelial Carcinoma took place on the 7th and 14th of October 2021 and was organized by the University Hospital La Paz, IdiPAZ and Grupo Centro de Tumores...
Compare your opinion with peers and Dr. Joost Boormans
Cystoscopy* has a high sensitivity for detecting carcinoma in situ (CIS) in non-muscle-invasive bladder cancer (NMIBC). Therefore, it can accurately rule out this high-grade and aggressive tumour. Submit your answer and read the opinion of Dr. Joost Boormans...
Using urinary markers for the detection of upper tract urothelial carcinoma
Reviewed by Mr. Hugh Mostafid “As EpiCheck® results are remarkable, this assay is now included in the diagnostic work-up of UTUC at our center.” [1] Urothelial carcinomas are most commonly found in the bladder, in which case they are referred to as bladder cancer....
Advantages of alternating Bladder EpiCheck® with cystoscopy
Reviewed by Professor Jørgen Bjerggaard Jensen (Aarhus University Hospital, Aarhus, Denmark) “A strategy alternating the urine marker Bladder EpiCheck® with cystoscopy in the surveillance of patients with low-grade intermediate-risk bladder cancer is cost-equivalent...
Compare your opinion with peers and Mr. Hugh Mostafid
True or false? The sensitivity and negative predictive value for detecting high-grade UTUC* is higher with Bladder EpiCheck compared to cytology. Submit your answer and read the opinion of Mr. Hugh Mostafid * Upper tract urothelial carcinomaShare this on...
New EAU 2022 guidelines: Urinary biomarkers for the surveillance of NMIBC
Watch the editorial comment by Prof. Dr. Paolo Gontero on biomarker statements in the new EAU 2022 guidelines. Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni...
Hey, it is bladder cancer awareness month in May!
The World Bladder Cancer Patient Coalition hosts this special month to highlight the facts about bladder cancer, promote awareness of the disease and call for more investment in research, treatment and care. The theme of this year’s edition “Don’t Go Red. Go To A...
How to improve conventional cystoscopy for bladder cancer diagnosis and follow-up?
Watch the case presentation of Dr. Ekaterina Laukhtina (Moscow, Russia) At the 19th Meeting of the EAU Section of Oncological Urology (ESOU22), held on 21-23 January 2022 in Madrid, Spain, Dr. Ekaterina Laukhtina presented a case with non-muscle invasive bladder...